Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiam Chemaitelly

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
Vaccine|July 30, 2025
Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over timeHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Plos One|September 26, 2025
Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysisHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 14, 2020
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure SettingLaith J Abu-Raddad, Hiam Chemaitelly, Joel A Malek, et al.
Influenza and Other Respiratory Viruses|September 29, 2024
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in QatarHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Journal of Medical Microbiology|May 16, 2022
Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settingsPeter V Coyle, Naema Hassan Al Molawi, Mohamed Ali Ben Hadj Kacem, et al.
Frontiers in Medicine|March 26, 2024
Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimationHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Influenza and Other Respiratory Viruses|November 29, 2023
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort studyMai A Mahmoud, Houssein H Ayoub, Peter Coyle, et al.
Eclinicalmedicine|May 3, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacyLaith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al.
JAMA|November 1, 2021
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Communications Medicine|July 2, 2025
Immune histories and natural infection protection during the omicron eraHiam Chemaitelly, Houssein H Ayoub, Niklas Bobrovitz, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Vaccine|July 30, 2025
Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over timeHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Plos One|September 26, 2025
Evaluating the cost-effectiveness of COVID-19 mRNA primary-series vaccination in Qatar: An integrated epidemiological and economic analysisHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 14, 2020
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure SettingLaith J Abu-Raddad, Hiam Chemaitelly, Joel A Malek, et al.
Influenza and Other Respiratory Viruses|September 29, 2024
BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in QatarHiam Chemaitelly, Houssein H Ayoub, Peter Coyle, et al.
Journal of Medical Microbiology|May 16, 2022
Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settingsPeter V Coyle, Naema Hassan Al Molawi, Mohamed Ali Ben Hadj Kacem, et al.
Frontiers in Medicine|March 26, 2024
Addressing bias in the definition of SARS-CoV-2 reinfection: implications for underestimationHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Influenza and Other Respiratory Viruses|November 29, 2023
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort studyMai A Mahmoud, Houssein H Ayoub, Peter Coyle, et al.
Eclinicalmedicine|May 3, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacyLaith J Abu-Raddad, Hiam Chemaitelly, Peter Coyle, et al.
JAMA|November 1, 2021
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in QatarLaith J Abu-Raddad, Hiam Chemaitelly, Houssein H Ayoub, et al.
Communications Medicine|July 2, 2025
Immune histories and natural infection protection during the omicron eraHiam Chemaitelly, Houssein H Ayoub, Niklas Bobrovitz, et al.
Pageof 16